Novartis | NVS - Current Liabilities

Stock Price
151.02
Daily Change
2.33 1.57%
Monthly
9.50%
Yearly
44.32%
Q1 Forecast
145.07

Novartis reported $32B in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 39.39B 376M Sep/2025
Amgen USD 21.79B 1.32B Sep/2025
AstraZeneca USD 34.05B 518M Sep/2025
Bausch Health Companies USD 4.79B 182M Sep/2025
Biogen USD 3.29B 106.3M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Canopy Growth CAD 81.1M 17.56M Sep/2025
Corcept Therapeutics USD 172.26M 27.6M Sep/2025
Drreddys Laboratories INR 1.76B 62.5M Dec/2025
Eli Lilly USD 40.14B 1.12B Sep/2025
Gilead Sciences USD 12.3B 1.11B Sep/2025
GlaxoSmithKline GBP 21.33B 956M Sep/2025
Glaxosmithkline GBP 28.68B 8.3B Sep/2025
J&J USD 50.87B 3.31B Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Novartis USD 32B 286M Sep/2025
Novartis USD 32B 286M Sep/2025
Pacira USD 107.08M 206.09M Sep/2025
Perrigo USD 1.15B 19.2M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Prestige Brands USD 134.6M 24.94M Sep/2025
Roche Holding CHF 28B 421M Dec/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Sanofi EUR 28.35B 9.32B Dec/2025
Supernus Pharmaceuticals USD 330.63M 44.27M Sep/2025
Zoetis USD 1.81B 1.56B Sep/2025